Serina Therapeutics (SER) - Bathi pungkasan

Stable laboratory operations and diagnostic system services maintain cycle continuity, which drives the current net income dynamics of Serina Therapeutics, Inc. (SER). Clinical trial successes and patent protection are stimulating growth. Capitalization is based on royalties and the licensing of technologies for the treatment of Parkinson's disease. Meanwhile, -0.02 serves as the base parameter value, capturing the issuer's final profitability level on the chart.

This indicator calculates the daily net income of Serina Therapeutics, Inc. (SER) based on operating flows, reaching a current value of -0.02. This metric distinguishes objective figures from market expectations, reflecting the efficiency of utilizing third-party plants to scale biopolymer platforms, which allows an investor to assess management quality and the risk of overpayment at peak values through the company's financial performance.